Medline — Financial Results

Revenue Grew 11.5% to $28.4 Billion, Almost Entirely from Volume

Medline's top line grew strongly, and the key detail here is that nearly all of the growth came from selling more products — not raising prices. New Prime Vendor relationships (long-term agreements where Medline serves as a customer's primary medical supply partner) added $1.2 billion alone, while existing Prime Vendor customers contributed another $1.0 billion.

Tariffs Hit Profit Margins Hard, Costing $290 Million in 2025

Even as sales surged, gross profit margin (the percentage of each sales dollar left after product costs) fell by almost a full percentage point. Tariffs (import taxes on goods from other countries) were the primary culprit, dragging the Medline Brand segment's profitability margin down by 2.35 percentage points on their own. The company expects tariffs to cost an additional $200 million in 2026 on top of the $290 million already absorbed, though it has levers to partially offset this — including shifting production and selectively raising prices.

Own-Brand Products Are More Profitable but Tariff-Exposed

The Medline Brand segment — products the company designs and sells under its own label — generates the vast majority of profits: $3.3 billion of the $4.1 billion in total segment earnings, despite representing just under half of total sales. However, this segment is also where tariffs bite hardest, since Medline manufactures and imports many of these products itself. Within existing Prime Vendor agreements, only 35% of sales are currently Medline Brand, meaning there is a large built-in opportunity to convert customers from third-party brands — which would improve margins, though it typically lowers the dollar value of each sale slightly.

IPO Raised $7 Billion and Paid Down Debt Significantly

In December 2025, Medline completed its initial public offering (IPO) on Nasdaq under the ticker MDLN, raising approximately $7.0 billion in net proceeds. The company used roughly $4.0 billion of that to pay off debt, eliminating all Euro-denominated loans and reducing its Dollar Term Loans. This also triggered a 0.25% reduction in the interest rate on remaining variable-rate debt. Total debt still stands at $12.8 billion, so Medline remains heavily leveraged (carrying a lot of borrowed money relative to its size), but the IPO meaningfully improved its debt profile.

Strong Cash Generation, but a Large Tax Obligation Looms

Operating cash flow was $1.74 billion in 2025, nearly matching 2024's $1.77 billion despite working capital headwinds from receivables and inventory build. However, investors should be aware of a significant long-term commitment: in connection with the IPO restructuring, Medline signed a tax receivable agreement obligating it to pay pre-IPO owners 90% of certain future tax benefits. The liability already recorded is $3.5 billion, with a potential additional $7.5 billion if all pre-IPO owners eventually exchange their units — payments spread over roughly 15 years.